New two-drug combo for KRAS G12C lung cancer as first treatment
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two targeted drugs (Fulzerasib and Ivonescimab) as a first treatment for advanced or metastatic lung cancer that has a specific KRAS G12C mutation. The goal is to see if this treatment works well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific genetic change called KRAS G12C in your lung cancer (confirmed by a lab test).
- You must not have already received any cancer treatment for your advanced-stage lung cancer (prior treatments for earlier stage are okay if it's been at least 6 months).
- You must be able to take care of yourself (ECOG score 0 or 1) – basically you are up and about most of the day.
- Your cancer must be measurable on scans (at least one tumor that can be measured).
- You must have adequate organ function (blood, liver, kidneys) – your doctor will check this with blood and urine tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with a specific type of lung cancer (KRAS G12C) that is still confined to the chest and can be surgically removed. It combines a targeted pill (garsorasib) followed by immunotherapy + chemotherapy before surgery, to see if this can shrink the tumor and improve outcomes.
This trial tests a combination of two drugs (Glecirasib and Ivonescimab) as the first treatment for people with non-small cell lung cancer that has a specific mutation called KRAS G12C and has spread or can't be removed by surgery. The goal is to see if this combination helps shrink tumors or slow the cancer down.
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
This Phase 1 study tests whether IBI351, a targeted medicine, can be safely given with standard chemotherapy to treat advanced lung cancer that has a KRAS G12C mutation. It’s mainly looking at safety and early signs of effectiveness, and may offer a new option if your cancer matches these features.
This trial tests a combination of two targeted drugs, IBI351 and Cetuximab beta, for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and hasn't been treated yet. The goal is to see if this combination can shrink tumors or slow cancer growth.
Hear when a new KRAS G12C Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.